Clinical Studies of Atovaquone, Alone or in Combination with other Antimalarial Drugs, for Treatment of Acute Uncomplicated Malaria in Thailand
about
Atovaquone-proguanil for treating uncomplicated malariaDrug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drugEndochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosisMitotic evolution of Plasmodium falciparum shows a stable core genome but recombination in antigen familiesTransformation with human dihydrofolate reductase renders malaria parasites insensitive to WR99210 but does not affect the intrinsic activity of proguanilAtovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity.The treatment of chloroquine-resistant malaria.Modelling parasite drug resistance: lessons for management and control strategies.Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system.Antimalarial pharmacology and therapeutics of atovaquoneCytochrome b mutation Y268S conferring atovaquone resistance phenotype in malaria parasite results in reduced parasite bc1 catalytic turnover and protein expressionWithin-host selection of drug resistance in a mouse model of repeated interrupted treatment of Plasmodium yoelii infection.Variations in frequencies of drug resistance in Plasmodium falciparum.Antimalarial drug therapy: the role of parasite biology and drug resistance.The chequered history of malaria control: are new and better tools the ultimate answer?A broad analysis of resistance development in the malaria parasitePrevention and treatment of malaria in pregnancy.Role of Different Pfcrt and Pfmdr-1 Mutations in Conferring Resistance to Antimalaria Drugs in Plasmodium falciparum.Azoreductases in drug metabolism.Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam.Challenges to replace ACT as first-line drug.Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic.In vitro and in vivo evaluation of betulinic acid as an antimalarial.The interaction of atovaquone with the P. carinii cytochrome bc1 complex.Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae.Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers.Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children.Long-acting injectable atovaquone nanomedicines for malaria prophylaxis.Exploring the trifluoromenadione core as a template to design antimalarial redox-active agents interacting with glutathione reductase.Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria
P2860
Q24245639-C7447577-9262-46E5-9890-A133FBCF2975Q24613311-5D92DC33-2359-41F6-A3B8-964AF25FA49DQ24630917-804B857E-55C6-4FCC-B3C7-8CD8249171A5Q28486079-9B1E8C62-F9BB-40F7-ADBF-34797FEA82B1Q29619882-D566514C-F1EC-4C09-AC49-4B07D03E6F9DQ30864028-AF419297-803D-48EF-948C-0726B3C5EFC4Q33711587-1FB3521B-E6C0-46EB-BC57-E5671C80B7F9Q34434816-9B4571C6-EC97-4178-B135-DA48A63B40B3Q34499482-28213264-591D-4777-892A-2342EDBB8C97Q35131253-9E376B69-A74D-4616-9327-50BA441CC931Q35879955-8CD30789-4297-4E06-8521-94582D4A4C53Q36378809-3BDCF9A3-9C7B-4F0F-90B9-EBC0889159BDQ36567189-24E567A9-663C-49A5-B1E2-75C4B5A0D9FDQ36652599-72205FDC-42D8-4F1A-A957-6BDB6CBCCB61Q36709695-6399EC34-D56A-4E35-893D-8CDC6CFCA14EQ37017711-3D2F5454-58B7-4F4F-869F-D1D1C8804392Q37809067-60554091-02B7-4968-8918-9E8EBED8F2EEQ38288177-344C37CD-26A7-4C47-84B6-20EBB53F61E9Q38917152-471C845C-D9BF-404A-8B1F-3E904F5CA8FAQ39022879-BAAF826A-4EED-40AB-B1BD-36FB3E466AC8Q39354871-65F59764-4297-46DA-BAF7-708E05A50704Q40106428-9BB13479-75CC-4CA5-BF62-938DF02D60A1Q41924375-6D2D06C9-9199-4902-8608-043782D7A86AQ43924747-D68EDA8D-CC94-439E-915D-BF05EB88D91EQ44630376-52AC2392-F991-4C69-9B4F-4E9885B68BE6Q46705598-5258DF0D-06B0-4743-BDE1-A0D71F57C577Q46828749-17F1E688-23AB-42F4-9AB4-691A8E69CB21Q47871895-19D2EABA-7356-4B76-8410-D2C6847055D3Q48022850-31A92FAD-5859-4D12-B08D-0007507C7C7AQ50510481-8E885BAF-3027-45B8-8BAA-3DC4A290F75AQ56770456-990FA801-D01F-457A-B8CD-8211FFEFCF1B
P2860
Clinical Studies of Atovaquone, Alone or in Combination with other Antimalarial Drugs, for Treatment of Acute Uncomplicated Malaria in Thailand
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 1996
@uk
name
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@en
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@nl
type
label
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@en
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@nl
prefLabel
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@en
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@nl
P2093
P356
P1476
Clinical Studies of Atovaquone ...... omplicated Malaria in Thailand
@en
P2093
Chaisin Viravan
Craig J. Canfield
David B. Hutchinson
H. Kyle Webster
P356
10.4269/AJTMH.1996.54.62
P407
P577
1996-01-01T00:00:00Z